In summary, KRAS mutations are among the most prevalent drivers of tumorigenesis, and their activation is correlated with tumor progression and poor prognosis.334,335 The evidence presented above strongly suggests that KRAS is a crucial tumor biomarker. This evidence concerns the gene KRAS and neoplasm.